Description

Neuroplant (Hypericum perforatum L.) Coated Tablets №20

Ingredients

Neuroplant tablets contain Hypericum perforatum L. extract as the active ingredient.

Dosage

The recommended dosage is 1 tablet daily, or as directed by a healthcare professional.

Indications

Neuroplant tablets are indicated for the management of mild to moderate depression and anxiety.

Contraindications

Do not use Neuroplant tablets if you are pregnant or breastfeeding without consulting a healthcare provider.

Directions

Take one tablet daily with water, preferably with a meal.

Scientific Evidence

Studies have shown that Hypericum perforatum L. extract, the key component of Neuroplant tablets, has demonstrated efficacy in treating mild to moderate depression. A meta-analysis published in the Cochrane Database of Systematic Reviews concluded that Hypericum perforatum L. is more effective than a placebo and is as effective as standard antidepressants in the treatment of depression.

Additional Information

Neuroplant tablets are coated for easy swallowing and are suitable for long-term use. It is important to note that individual responses to the medication may vary, and it is recommended to consult a healthcare professional before starting any new supplement regimen.

Pharmacological Effects: Hypericum perforatum L. works by inhibiting the reuptake of serotonin, dopamine, and norepinephrine, which are neurotransmitters involved in mood regulation. This mechanism of action is similar to that of conventional antidepressants, providing a natural alternative for individuals seeking relief from depression and anxiety.

Clinical Trials: Several clinical trials have evaluated the efficacy of Hypericum perforatum L. in the treatment of depression. A randomized controlled trial published in the Journal of Affective Disorders found that Hypericum perforatum L. was well-tolerated and significantly reduced depressive symptoms compared to a placebo. These findings support the use of Neuroplant tablets as a safe and effective option for individuals with mild to moderate depression.